Michael Thomas Heffernan Collegium Pharmaceutical, Inc (COLL) insider trading activity

Michael Thomas Heffernan is Director of COLLEGIUM PHARMACEUTICAL, INC. Currently has a direct ownership of 45,508 shares of COLL, which is worth approximately $1.58 Million. The most recent transaction as insider was on May 16, 2024, when has been sold 7,693 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45.5K

0% 3M change

20.34% 12M change

Total Value Held $1.58 Million

Michael Thomas Heffernan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 16 2024	BUY Grant, award, or other acquisition	-	7,693 Added 14.46%	45,508 Common Stock
May 18 2023	BUY Grant, award, or other acquisition	-	9,792 Added 20.57%	37,815 Common Stock
Dec 27 2022	SELL Open market or private sale	$473,578 $23.9 p/Share	19,815 Reduced 41.42%	28,023 Common Stock
Dec 27 2022	BUY Exercise of conversion of derivative security	$320,012 $16.15 p/Share	19,815 Added 38.36%	31,843 Common Stock
Dec 23 2022	SELL Open market or private sale	$114,747 $23.0 p/Share	4,989 Reduced 15.11%	28,023 Common Stock
Dec 23 2022	BUY Exercise of conversion of derivative security	$80,572 $16.15 p/Share	4,989 Added 13.13%	33,012 Common Stock
Dec 22 2022	SELL Open market or private sale	$5,451 $23.0 p/Share	237 Reduced 0.84%	28,023 Common Stock
Dec 22 2022	BUY Exercise of conversion of derivative security	$3,827 $16.15 p/Share	237 Added 0.83%	28,260 Common Stock
Dec 21 2022	SELL Open market or private sale	$1,076,926 $23.11 p/Share	46,600 Reduced 62.45%	28,023 Common Stock
Dec 21 2022	BUY Exercise of conversion of derivative security	$752,589 $16.15 p/Share	46,600 Added 38.44%	74,623 Common Stock
Dec 20 2022	SELL Open market or private sale	$779,134 $23.08 p/Share	33,758 Reduced 54.64%	28,023 Common Stock
Dec 20 2022	BUY Exercise of conversion of derivative security	$545,191 $16.15 p/Share	33,758 Added 35.33%	61,781 Common Stock
Dec 19 2022	SELL Open market or private sale	$83,082 $23.04 p/Share	3,606 Reduced 11.4%	28,023 Common Stock
Dec 19 2022	BUY Exercise of conversion of derivative security	$58,236 $16.15 p/Share	3,606 Added 10.23%	31,629 Common Stock
Dec 13 2022	SELL Open market or private sale	$3,582,983 $22.16 p/Share	161,687 Reduced 85.23%	28,023 Common Stock
Dec 13 2022	BUY Exercise of conversion of derivative security	$2,410,753 $14.91 p/Share	161,687 Added 46.01%	189,710 Common Stock
Dec 12 2022	SELL Open market or private sale	$614,519 $22.01 p/Share	27,920 Reduced 49.91%	28,023 Common Stock
Dec 12 2022	BUY Exercise of conversion of derivative security	$416,287 $14.91 p/Share	27,920 Added 33.29%	55,943 Common Stock
May 19 2022	BUY Grant, award, or other acquisition	-	14,035 Added 33.37%	28,023 Common Stock
May 20 2021	BUY Grant, award, or other acquisition	-	9,941 Added 41.54%	13,988 Common Stock
Mar 15 2021	SELL Open market or private sale	$1,280,418 $25.57 p/Share	50,075 Reduced 92.52%	4,047 Common Stock

Also insider at

SYBX

SYNLOGIC, INC. Healthcare

BHVN

Biohaven Pharmaceutical Holding Co Ltd. Healthcare

AKBA

Akebia Therapeutics, Inc. Healthcare

TRVI

Trevi Therapeutics, Inc. Healthcare

BHVN

Biohaven Ltd.

MTH